Cannabis-based medicines have emerged as a promising therapeutic for a variety of neuropsychiatric disorders, including autism spectrum disorder (ASD). This manuscript encompasses research investigating the application of the phytocannabinoid cannabidiol (CBD) in treating core symptoms of ASD. Chapter one includes a literature review of the neurodevelopmental etiology and current pharmacological strategies for ASD. The second chapter is a paper illustrating the prosocial effects of CBD and cannabis-inspired terpenes in our mouse model of ASD. The third chapter is a pilot study looking into the developmental pathology and adolescent exposure to CBD as an interventional strategy in our preclinical model. This work and continued research can inform cannabis-based treatments for ASD in the effort to improve quality of life and offer wider accessibility to medications for affected individuals
